STOCK TITAN
  1. Home
  2. News
  3. BDX

Becton Dickinson & Co. - BDX STOCK NEWS

Welcome to our dedicated news page for Becton Dickinson & Co. (Ticker: BDX), a resource for investors and traders seeking the latest updates and insights on Becton Dickinson & Co..

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Becton Dickinson & Co.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Becton Dickinson & Co.'s position in the market.

News
BD Initiates International Study to Expand Treatment Options for Patients with Peripheral Arterial Disease
Rhea-AI Summary
BD announces the enrollment of the first patient in the AGILITY study to assess the safety and effectiveness of the BD Vascular Covered Stent for PAD treatment. The study includes 315 patients across multiple countries and aims to address the significant unmet needs in treating PAD patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.14%
Tags
none
-
News
Dave Hickey Announces Intent to Retire from BD
Rhea-AI Summary
BD (Becton, Dickinson and Company) announces the retirement of Dave Hickey, the current executive vice president and president of the Life Sciences segment effective July 1. Hickey has been with BD since 2014 and has made significant contributions, especially during the COVID-19 pandemic. BD plans to name a successor before his retirement date.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.2%
Tags
none
-
News
BD Partners with Camtech Health to Increase Access to Cervical Cancer Screening in Singapore
Rhea-AI Summary
BD (Becton, Dickinson and Company) partners with Camtech Health to offer at-home self-collection of samples for HPV testing in Singapore, aiming to improve cervical cancer screening rates. The program combines Camtech Health's HPV test for self-collection with BD's Onclarity™ HPV Assay, detecting 14 high-risk HPV strains. The initiative addresses barriers like lack of time, embarrassment, and fear, providing women greater access to screening. The World Health Organization's Global Strategy to Eliminate Cervical Cancer by 2030 recognizes the potential of at-home testing to reach more women and prevent cervical cancer cases caused by HPV infections.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.94%
Tags
partnership
News
BD to Present at Investor Healthcare Conferences
Rhea-AI Summary
BD (Becton, Dickinson and Company) to present at Citi's 2024 Unplugged Medtech and Life Sciences Access Day and Barclays 26th Annual Global Healthcare Conference. Webcasts available on investors.bd.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.33%
Tags
conferences
-
News
BD to Present Next Installment of BD Innovates Series: Spotlight on Peripheral Vascular Disease
Rhea-AI Summary
BD (Becton, Dickinson and Company) announces the next installment of its BD Innovates series focusing on solutions for Peripheral Vascular Disease. The presentation will highlight innovations supporting BD's 2025 Strategy, emphasizing the Peripheral Vascular Disease platform within the BD Peripheral Intervention business unit.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.77%
Tags
conferences
-
News
BD Reports First Quarter Fiscal 2024 Financial Results
Rhea-AI Summary
BD (Becton, Dickinson and Company) reported Q1 revenue of $4.7 billion, a 2.6% increase as reported, with 1.6% currency-neutral and 2.4% organic growth. GAAP and adjusted diluted EPS from continuing operations were $0.96 and $2.68, respectively. The company raised full-year adjusted EPS guidance and midpoint of organic revenue growth guidance for fiscal 2024. BD Medical, BD Life Sciences, and BD Interventional segments showed varying revenue changes. The company also provided an outlook for fiscal 2024, raising the lower end and midpoint of its fiscal 2024 organic revenue growth guidance range, and increasing its adjusted diluted earnings per share guidance range.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.48%
Tags
earnings
News
BD, Techcyte Announce Strategic Collaboration to Offer AI-Based Digital Cervical Cytology System for Pap Testing
Rhea-AI Summary
BD (Becton, Dickinson and Company) and Techcyte have announced a strategic collaboration to offer an AI-based algorithm that guides cytologists and pathologists to efficiently identify evidence of cervical cancer and precancer using whole-slide imaging. The solution aims to reduce human error, increase throughput, and deliver consistent results for patients. The system is compatible with common liquid-based cytology preparations and aims to be available in Europe in the first half of 2024, pending FDA approval for clinical use in the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.69%
Tags
AI
-
News
BD Helps Advance Health Equity for Women in Kenya through Critical Cancer Screening
Rhea-AI Summary
BD (Becton, Dickinson and Company) (NYSE: BDX) has announced a collaboration with the Kenyan Government through the National Cancer Institute-Kenya to expand access to critical cancer diagnostics for women in Kenya. The initiative aligns with the Ministry of Health Kenya's Cancer Control Strategy and aims to address the prevention and control of all cancers, with a focus on cervical and breast cancer. The collaboration also supports the World Health Organization's efforts to eliminate cervical cancer by 2030. Cervical cancer is a significant global health issue, with 604,000 new cases and 342,000 deaths in 2020.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.85%
Tags
none
-
News
BD Board Declares Dividend
Rhea-AI Summary
BD (Becton, Dickinson and Company) has declared a quarterly dividend of $0.95 per common share, with an indicated annual dividend rate of $3.80 per share. The dividend is payable on March 29, 2024, to holders of record on March 8, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.57%
Tags
dividends
News
BD, Hamilton Collaborate to Standardize Single-Cell Multiomics Experiments Using Robotics
Rhea-AI Summary
BD (Becton, Dickinson and Company) has announced a collaboration agreement with Hamilton to develop automated applications and robotics-compatible reagent kits for single-cell multiomics experiments. The collaboration aims to standardize and reduce human error in large-scale experiments, with the goal of automating pipetting and thermal cycling to produce DNA samples ready for genetic sequencing. The companies aim to deliver a complete solution for researchers to achieve reliable results with greater throughput, with the products set to be released in phases starting in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.02%
Tags
none
Stock BDX logo
Becton Dickinson & Co.

NYSE:BDX

BDX Rankings

#185 Ranked by Market Cap
#1535 Ranked by Stock Gains
#1554 Ranked by Dividends

BDX Stock Data

66.74B
288.20M
0.31%
89.29%
1.01%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Franklin Lakes

About BDX

Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, and others.